DynaKin is a stakeholder owned company collaborating with small to large pharmaceutical and biotechnology companies often in combination with research centers, hospital services and universities, for the development of new drugs and therapeutic strategies. 

Our quantified advantage is in our combination of GLP bioanalysis and Pharmacokinetic / Pharmacodynamic (PK/PD) Modeling & Simulation offering high added value consulting for strategic decision making, all under the same roof. Our operational advantage is in high quality, flexibility, rigor, high reactivity and our securitized and traceable data and model management processes.

The Bioanalysis branch provides bioanalytical support for your regulatory Pharmacokinetic or Toxicokinetic studies in compliance with GLP. Our state-of-the-art laboratory and top class international personnel offers a scientific - technological advantage allowing the quantification of a wide range of compounds in different biological matrices through all stages of the R&D process (LC/MS-MS, HPLC-UV, etc.).

Dynakin’s Drug Modeling & Consulting (DMC) services & partners offers strong know-how to optimize the development of drugs using pharmaco-statistical models that summarize PK and PD information from the different phases of drug development. This PK/PD Modeling & Simulation based consulting, following the translational development, Model Based Drug Development (MBDD) paradigm, aims to assist in strategic decision making for drug development. MBDD constitutes an important component of the FDA Critical Path Initiative.

Dynakin has wide experience with regulatory protocol and report submission, presentation and follow-up. The group’s expertise covers all therapeutic areas and patient groups, including oncology and pediatrics.